Tag Archives: Gilead Sciences

Challenges in the March Toward an AIDS-Free Generation

FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.
Posted in Biotech, Events, FDA, healthcare, Market Access, Patient Communication, patient compliance, patient education, pricing, Regulatory, Safety | Also tagged , , , , , , | Leave a comment

HIV Market Banking on Fixed-Dose Treatments

The HIV markets are expected to grow for the next two years, but major patent expirations in the following years will have a huge impact on pharmaceutical sales by 2019, according to a new report by DataMonitor. Antiretroviral sales in 2009 were estimated at $11.8 billion. While that figure is forecast to hit $14.4 billion […]
Posted in R&D | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta